Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2017, Article ID 3182129, 10 pages
https://doi.org/10.1155/2017/3182129
Research Article

Thiazolopyridines Improve Adipocyte Function by Inhibiting 11 Beta-HSD1 Oxoreductase Activity

1Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
2Plants for Human Health Institute, North Carolina State University, North Carolina Research Campus, 600 Laureate Way, Kannapolis, NC 28081, USA
3Department of Food, Bioprocessing, and Nutrition Sciences, North Carolina State University, 400 Dan Allen Drive, Raleigh, NC 27695, USA
4Department of Animal Science, North Carolina State University, 120 Broughton Drive, Raleigh, NC 27695, USA
5Department of Plant and Microbial Biology, North Carolina State University, 100 Derieux Place, Raleigh, NC 27695, USA
6Center for Synthesis and Chemical Biology, Institute of Science, Universiti Teknologi MARA, 40450 Shah Alam, Selangor Darul Ehsan, Malaysia

Correspondence should be addressed to Slavko Komarnytsky; ude.uscn@ykstynramok

Received 25 December 2016; Revised 26 February 2017; Accepted 12 March 2017; Published 29 March 2017

Academic Editor: Shengmin Sang

Copyright © 2017 Thirumurugan Rathinasabapathy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases, WHO Press, Geneva, Switzerland, 2008.
  2. C. D. Fryar, M. D. Carroll, and C. L. Ogden, Prevalence of Overweight, Obesity, and Extreme Obesity among Adults: United States, Trends 1960–1962 through 2009-2010, National Center for Health Statistics, Hyattsville, Md, USA, 2012.
  3. Institute of Public Health, Prevalence of Non Communicable Diseases and Nutritional Status of Malaysian Adults, National Health and Morbidity Survey, 2011.
  4. M.-J. Lee, P. Pramyothin, K. Karastergiou, and S. K. Fried, “Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1842, no. 3, pp. 473–481, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. B. R. Walker, “Cortisol—cause and cure for metabolic syndrome?” Diabetic Medicine, vol. 23, no. 12, pp. 1281–1288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Rask, T. Olsson, S. Söderberg et al., “Tissue-specific dysregulation of cortisol metabolism in human obesity,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 3, pp. 1418–1421, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Valsamakis, A. Anwar, J. W. Tomlinson et al., “11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus,” The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4755–4761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Draper, E. A. Walker, I. J. Bujalska et al., “Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency,” Nature Genetics, vol. 34, no. 4, pp. 434–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Kotelevtsev, M. C. Holmes, A. Burchell et al., “11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 26, pp. 14924–14929, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. N. M. Morton, M. C. Holmes, C. Fiévet et al., “Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice,” The Journal of Biological Chemistry, vol. 276, no. 44, pp. 41293–41300, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Masuzaki, J. Paterson, H. Shinyama et al., “A transgenic model of visceral obesity and the metabolic syndrome,” Science, vol. 294, no. 5549, pp. 2166–2170, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Sun, M. Wang, and Z. Wang, “Small molecule 11β-hydroxysteroid dehydrogenase type 1 inhibitors,” Current Topics in Medicinal Chemistry, vol. 11, no. 12, pp. 1464–1475, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Hult, H. Jörnvall, and U. C. T. Oppermann, “Selective inhibition of human type 1 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics,” FEBS Letters, vol. 441, no. 1, pp. 25–28, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Morgan, M. Sherlock, L. L. Gathercole et al., “11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle,” Diabetes, vol. 58, no. 11, pp. 2506–2515, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Rosenstock, S. Banarer, V. A. Fonseca et al., “The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy,” Diabetes Care, vol. 33, no. 7, pp. 1516–1522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. P. U. Feig, S. Shah, A. Hermanowski-Vosatka et al., “Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome,” Diabetes, Obesity and Metabolism, vol. 13, no. 6, pp. 498–504, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Nixon, D. J. Wake, D. E. Livingstone et al., “Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization,” Diabetes, vol. 61, no. 4, pp. 790–796, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Aronov, U. P. Bandarage, K. M. Cottrell et al., “Tetrahydrothiazolopyridine inhibitors of phosphaidylinositol 3-kinase,” US Patent Application, 2012/0039849A1, 2011.
  19. N. Haginoya, S. Komoriya, K. Osanai et al., “Facile methods for preparation of thiazolopyridine and tetrahydrothiazolopyridine derivatives,” Heterocycles, vol. 63, no. 7, pp. 1555–1561, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Gazit, P. Yaish, C. Gilon, and A. Levitzki, “Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors,” Journal of Medicinal Chemistry, vol. 32, no. 10, pp. 2344–2352, 1989. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Hermanowski-Vosatka, J. M. Balkovec, K. Cheng et al., “11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice,” The Journal of Experimental Medicine, vol. 202, no. 4, pp. 517–527, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Alberti, A. Girola, L. Gilardini et al., “Type 2 diabetes and metabolic syndrome are associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjects,” International Journal of Obesity, vol. 31, no. 12, pp. 1826–1831, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Kizelsztein, D. Govorko, S. Komarnytsky et al., “20-Hydroxyecdysone decreases weight and hyperglycemia in a diet-induced obesity mice model,” American Journal of Physiology-Endocrinology and Metabolism, vol. 296, no. 3, pp. E433–E439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Mehra, I. Macdonald, and T. S. Pillay, “Variability in 3T3-L1 adipocyte differentiation depending on cell culture dish,” Analytical Biochemistry, vol. 362, no. 2, pp. 281–283, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Winer, C. K. S. Jung, I. Shackel, and P. M. Williams, “Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro,” Analytical Biochemistry, vol. 270, no. 1, pp. 41–49, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. R. E. Duncan, M. Ahmadian, K. Jaworski, E. Sarkadi-Nagy, and H. S. Sul, “Regulation of lipolysis in adipocytes,” Annual Review of Nutrition, vol. 27, pp. 79–101, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. I. J. Bujalska, E. A. Walker, M. Hewison, and P. M. Stewart, “A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells,” The Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3, pp. 1205–1210, 2002. View at Publisher · View at Google Scholar · View at Scopus